Applied Optoelectronics, a producer of fiber-optic networking products, is expanding its headquarters and manufacturing campus in Sugar Land, Texas. The $30 million project includes construction of 111,600 sf of space for R&D, manufacturing, and administration. Completion is expected in late 2015.
Stelis Biopharma has selected Bio-XCell to construct a $60 million biopharmaceutical manufacturing facility in Nusajaya in the Johor region of Malaysia. Providing mammalian and microbial production suites, the 140,000-sf project will feature next-generation, single-use bioprocessing technologies. Completion is expected in late 2016 with operations commencing in mid-2017. Stelis Biopharma is a wholly-owned subsidiary of Strides Arcolab.
Bristol-Myers Squibb will build a 323,000-sf biologics manufacturing facility in Dublin, Ireland. Located on the company's existing pharmaceutical production campus, the building will provide open labs and offices, six 15,000-liter bioreactors, and a purification area. The estimated construction cost of the project is $900 million. The facility will accommodate up to 400 employees and is expected to be fully operational in 2019.
Thermo Fisher Scientific dedicated the $85 million Niche Diagnostics Center of Excellence in October of 2014 in Fremont, Calif. The 350,000-sf R&D facility will support the creation and production of advanced diagnostic testing and quality control products. Housing 500 employees, the sustainably designed center features a sophisticated HVAC system and low-flow water fixtures.
XBiotech broke ground in September of 2014 on a 46,000-sf pharmaceutical research and manufacturing center in Austin, Texas. The $12 million facility will reach completion in mid-2015 with production of the cancer drug Xilonix commencing in early 2016. The project is part of a $200 million campus that XBiotech plans to develop on the 48-acre site.
Merck broke ground in August of 2014 on a $108 million pharmaceutical manufacturing plant in Nantong, China. Located in the BioSpark development, the 430,560-sf facility will produce therapeutics for the treatment of cardiovascular diseases, thyroid disorders, and diabetes. The highly efficient project is designed to minimize waste during the manufacturing process. Completion is expected in 2016 with commercial operations commencing in 2017.
Global consumer products manufacturer Unilever will begin construction in September of 2014 on the $108 million Materials Innovation Factory in Liverpool. Created in partnership with the University of Liverpool, the 120,000-sf facility will accommodate 250 investigators engaged in materials chemistry research. Completion is expected in summer of 2016. Unilever is also opening the $11.4 million, 43,000-sf High Throughput Formulation Centre in the Liverpool Science Park.
The UK Atomic Energy Authority will begin construction in 2015 on the $26.2 million Remote Applications in Challenging Environments (RACE) facility in Abingdon in the United Kingdom. Located at the Culham Science Centre, the 32,300-sf project will provide advanced R&D labs for the creation of robotic technologies for nuclear, aerospace, construction, mining, and marine applications. Completion is expected by early 2016.
Merck will begin construction in August of 2014 on a 430,000-sf pharmaceutical production plant in Shanghai. The $107 million facility will manufacture drugs for diabetes as well as thyroid and heart conditions. Completion is expected in 2016 and commercial production will begin in 2017.
Emerson Climate Technologies will begin construction in October of 2014 on a 40,000-sf facility located on the University of Dayton campus. The Innovation Center will support the development of advanced heating, ventilation, air conditioning, and refrigeration (HVACR) technologies and will house up to 50 employees. The construction cost of the facility is approximately $20 million with a total project cost of between $35 million and $40 million.
Purdue Pharma Manufacturing will build a 188,000-sf production plant in the Treyburn Corporate Park in Durham, N.C. The project will provide cleanrooms with epoxy-coated floors, walls, and ceilings for the manufactucture of oral solid dosage products. The facility will also include offices, labs, conference rooms, and training areas. The general contractor is KBR Building Group. The facility is part of Purdue Pharma's planned $59 million investment in the Durham site over the next three years.
Microelectronics manufacturer Entegris completed construction in July of 2014 on the $30 million i2M Center for Advanced Materials in Bedford, Mass. An existing building was renovated to create an 80,000-sf R&D facility housing cleanrooms, labs, production and assembly space, and offices. BIM (Building Information Modeling) was leveraged in the delivery of the the project, which included installation and coordination of new building systems for HVAC, electrical, fire protection, gas detection, and laboratory utilities.
NanoViricides has completed its pharmaceutical manufacturing facility in Shelton, Conn. Designed by Id3A, the renovation project created research labs, offices, and cGMP cleanroom suites for the production of active pharmaceutical ingredients (APIs) in an existing 18,000-sf facility. MPH Engineering was the project manager and engineering consultant. Construction began on the facility in August of 2013 and validation commenced in June of 2014.
The University of Manitoba is partnering with Magellan Aerospace to create the Advanced Satellite Integration Facility. The 6,000-sf ASIF will be located at Magellan's Winnipeg site and will be jointly funded and operated with the University. The project will support the simultaneous assembly, integration, and testing of up to three satellite buses, and will also serve as a training center for satellite engineering and production.
WuXi PharmaTech broke ground in May of 2014 on a production facility for cell therapies in Philadelphia. The 45,000-sf clinical and commercial manufacturing project will feature flexible cleanrooms in a modular building design. Located in the Philadelphia Navy Yard, the cGMP facility is expected to begin production in the second quarter of 2015.
